Evolving standards of care and new challenges in the management of HER2‐positive breast cancer
2020 · CA A Cancer Journal for Clinicians · 189 citations
https://doi.org/10.3322/caac.21634
C
Ciara C. O’Sullivan
Mayo Clinic(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
143
Papers
2.0K
Citations
23
h-index
34
i10-index
Ciara C. O’Sullivan is an academic researcher from Mayo Clinic. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies. The author has an h-index of 23, co-authored 122 publications.
ORCID: 0000-0001-6069-9800Papers by this author
worksEfficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
2015 · Journal of Clinical Oncology · 103 citations
https://doi.org/10.1200/jco.2015.60.8620
Current challenges in the management of breast cancer brain metastases
2017 · Seminars in Oncology · 56 citations
https://doi.org/10.1053/j.seminoncol.2017.06.006
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
2023 · Annals of Oncology · 50 citations
https://doi.org/10.1016/j.annonc.2023.09.3103
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer
2023 · JAMA Oncology · 49 citations
https://doi.org/10.1001/jamaoncol.2022.7949
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer
2023 · JAMA Oncology · 48 citations
https://doi.org/10.1001/jamaoncol.2023.2000
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat